Type 2 diabetes: retatrutide cut HbA1c by up to 2.2 points in 36 weeks

In phase 2 it outperformed placebo and dulaglutide on glucose control, with weight loss of up to 16.9%.

This phase 2 trial, published in The Lancet, enrolled adults with type 2 diabetes and HbA1c between 7.0 and 10.5%. Weekly retatrutide was compared with placebo and with dulaglutide, another GLP-1 agonist.

At 36 weeks, HbA1c fell by up to 2.2% with retatrutide, versus 1.4% with dulaglutide and 0.3% with placebo. Body weight fell by up to 16.9%, in a dose-dependent way.

In three points

Phase 2 human trial in type 2 diabetes
HbA1c down up to 2.2% vs 1.4% with dulaglutide
Body weight down up to 16.9% at 36 weeks

Compounds mentioned

Retatrutide

Original source: Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
The Lancet

Plain-language summary by SYNTRA LABS based on the original publication and checked against its source. It is not medical advice or a recommendation for use. SYNTRA LABS compounds are for research use only and not for human consumption.